Table 3.
Spearman correlation coefficient values for the correlation between chondrogenic outcome (GAG/DNA and histology scores) and baseline expression of genetic and surface markers.
GAG/DNA (n = 15) |
Histology score (n = 9) |
|||
---|---|---|---|---|
r | p values | r | p values | |
Genetic markers | ||||
SOX9 | 0.02 | 0.98 | 0.41 | 0.31 |
COL2A1 | 0.50 | 0.07a | −0.48 | 0.23 |
ACAN | 0.33 | 0.25 | −0.22 | 0.62 |
FRZB | −0.01 | 0.97 | 0.29 | 0.50 |
COL10A1 | 0.17 | 0.55 | −0.57 | 0.14 |
ALK1 | 0.07 | 0.8 | −0.29 | 0.48 |
Surface marker | ||||
CD49c | −0.20 | 0.40 | −0.04 | 0.90 |
CD166 | 0.043 | 0.88 | −0.18 | 0.64 |
CD39 | −0.08 | 0.79 | −0.25 | 0.52 |
CD271 | 0.44 | 0.11 | 0.08 | 0.85 |
CD73 | −0.03 | 0.91 | −0.14 | 0.71 |
CD90 | −0.51 | 0.06a | −0.11 | 0.78 |
CD105 | −0.28 | 0.30a | −0.16 | 0.69 |
CD14 | −0.43 | 0.11 | −0.38 | 0.32 |
CD34 | −0.18 | 0.63 | 0.003 | 0.99 |
When the outlier of patient 4 was excluded from analyses, correlations were significant as follows: COL2A1 (r = 0.7, p = 0.006); CD90 (r = −0.6, p = 0.03); CD105 (r = −0.55, p = 0.04).